UnknownNot Applicable

Prospective Multicenter Study on Clinical Application of Sonazoid in Liver Tumor

1,300 participantsStarted 2020-10-01

Plain-language summary

Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of Sonazoid specific angiography and his mechanical index, the role of Sonazoidin in the differential diagnosis of benign and malignant focal liver lesions in different liver background was explored

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1.Chinese citizen, ≥ 18 years old; 2.Conventional ultrasound shows that there is definite lesion in the liver, and there is liver parenchyma around the lesion; 3.There is enhanced MRI or enhanced CT finding. For patients with liver fibrosis after hepatitis, the results of liver parenchyma elastography can be added (optional); 4. If the subjects are female, they should be non pregnant and lactating women; 5.Patients voluntarily participate in the study and signe informed consent Exclusion Criteria: * 1.Subjects are known to be allergic to Perfluorobutane or any component of Sonazoid; 2.Patients with severe heart disease or severe lung disease; 3.Pregnant, potential pregnant or lactating patients; 4.No enhanced MRI or CT results are available; 5.The researchers consider that the subjects are not suitable for this study

What they're measuring

Diagnostic performance of contrast-enhanced ultrasound in different liver background and liver turmors by sonazoid

Timeframe: 10 months

Trial details

NCT IDNCT04563897

SponsorChinese PLA General Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-05-01

View on ClinicalTrials.gov More Ultrasound trials